Hisham Alrefai, MD
Endocrinology, Diabetes & Metabolism · Louisville, KYNPI 1811962350
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $614,820 of the $720,023 with a category attached, or 85.4%. 60 manufacturers reported payments, led by Novo Nordisk at 34.1% of the total. Reporting peaked in 2019 at $254,598 and has fallen 58.9% since, to $104,677 in 2025. Among endocrinology, diabetes & metabolism clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,474 payments — averaging $291.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$245K
- Insulet Corporation$121K
- AstraZeneca$81K
- Bayer$73K
- Amgen$66K
- Corcept Therapeutics$51K
- plus $83K from 54 others
What the payments were for
- Speaking & faculty fees$614,82085%
- Travel & lodging$57,9678%
- Food & beverage$46,6776%
- Education$5580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$119,055
- Ozempic$118,298
- FARXIGA$78,125
- RYBELSUS$73,357
- Kerendia$70,925
- Repatha$64,073
- Korlym$48,018
- Vascepa$45,755
- Tresiba$32,514
- V-GO$14,522
- Xultophy 100/3.6$6,588
- CeQur Simplicity$2,523
- t-slim insulin pump$1,700
- MINIMED 770G$1,533
- MINIMED 780G$321
- MYALEPT$300
- TEPEZZA$252
- t:slim X2 insulin pump$250
- LOKELMA$185
- TLANDO$132
How this compares
$720,023 in reported general payments places this provider in the 95th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 818 | $1,112,441 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 408 | $400,789 |
| Tresiba Flextouch U-200Insulin Degludec | 223 | $380,574 |
| Humulin R U-500Insulin Regular, Human | 228 | $350,917 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 260 | $313,150 |
| MounjaroTirzepatide | 196 | $240,400 |
| FarxigaDapagliflozin Propanediol | 241 | $212,145 |
| TrulicityDulaglutide | 116 | $175,996 |
| RybelsusSemaglutide | 109 | $171,981 |
| Tresiba Flextouch U-100Insulin Degludec | 181 | $171,963 |
| JardianceEmpagliflozin | 123 | $119,401 |
| Cequr SimplicityBolus Insulin Pump, 200 Unit | 218 | $114,994 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 504 | $113,466 |
| VascepaIcosapent Ethyl | 155 | $85,224 |
| Novolog FlexpenInsulin Aspart | 198 | $83,994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp, Wegovy | $245,335 | $1,456,2611,191 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $22 | $498,392554 claims |
| AstraZenecaFarxiga | $81,460 | $212,145241 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $1,309 | $144,207155 claims |
| Cequr CorporationCequr Simplicity | $2,523 | $114,994218 claims |
| MerckJanuvia, Janumet Xr | $432 | $75,03177 claims |
| BayerKerendia | $72,525 | $68,37678 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $904 | $58,585105 claims |
| AbbVieSynthroid | $873 | $51,684626 claims |
| Radius Health, Inc.Tymlos | $49 | $37,13512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Louisville
- Harold BaysLouisville$214K
- Jahangir CyrusLouisville$155K
- Mehdi PoorkayLouisville$81K
- Angelino YsonLouisville$15K
- Mary SelfLouisville$14K
- Omolara FakunleLouisville$13K
- Kaitlyn TuckerLouisville$9K
- Manikya KuritiLouisville$7K
- Carol ToumaLouisville$5K
- Swapna DeoLouisville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.